Pharmacology of ocular allergy

Current Opinion in Allergy and Clinical Immunology

Volumn 6, Issue 5, 2006, Pages 383-389

  Schultz, Beth Lillian ^a,b  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b NONE   (United States)

Author keywords

Eosinophils; Histamine; Intercellular adhesion molecule 1; Interleukins; Leukotrienes; Prostaglandins

Indexed keywords

ALLERGEN; ANTIHISTAMINIC AGENT; AZELASTINE; CETIRIZINE; CORTICOSTEROID; CROMOGLYCATE DISODIUM; CYTOKINE; DESLORATADINE; EMEDASTINE; EPINASTINE; FEXOFENADINE; HISTAMINE; IMMUNOGLOBULIN E; INTERCELLULAR ADHESION MOLECULE 1; KETOROLAC TROMETAMOL; KETOTIFEN; LEUKOTRIENE; LEVOCABASTINE; LODOXAMIDE; LORATADINE; NEDOCROMIL SODIUM; NONSTEROID ANTIINFLAMMATORY AGENT; OLOPATADINE; PEMIROLAST; PREDNISONE ACETATE; PROSTAGLANDIN; STABILIZING AGENT; TUMOR NECROSIS FACTOR; UNINDEXED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

CHEMOSIS; CLINICAL TRIAL; CONJUNCTIVA; DRUG MECHANISM; EOSINOPHIL; EYE ALLERGY; HUMAN; MAST CELL; NEUTROPHIL; OCULAR PRURITUS; PRIORITY JOURNAL; PROVOCATION TEST; REVIEW; SWELLING; SYMPTOMATOLOGY; TREATMENT OUTCOME;

CONJUNCTIVITIS, ALLERGIC; HISTAMINE ANTAGONISTS; HUMANS;

EID: 33748568136     PISSN: 15284050     EISSN: 14736322     Source Type: Journal    
DOI: 10.1097/01.all.0000244801.79475.66     Document Type: Review

References (58)

1. World Health Organization (WHO) and World Allergy Organization-IAACI (WAO). Prevention of Allergy and Allergic Asthma. Joint Meeting between WHO and WAO, Geneva, 8-9 January 2002. Geneva: WHO Document Production Services, 2003.
2. The International Study of Asthma and Allergies in Childhood (ISAAC) Steering Committee. Worldwide variation in prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and atopic eczema: ISAAC. Lancet 1998; 351:1225-1232.
3. Bousquet J, Bousquet PJ, Godard P, et al. The public health implications of asthma. Bull Wld Hlth Org 2005; 83:548-554.
4. Abelson MB, Loeffler O. Conjunctival allergen challenge: models in the investigation of ocular allergy. Curr Allergy Asthma Rep 2003; 3:363-368.
5. Yanni JM, Sharif NA, Gamache DA, et al. A current appreciation of sites for pharmacological intervention in allergic conjunctivitis: effects of new topical ocular drugs. Acta Ophthalmol Scand 1999; 77 (Suppl. 228):33-37.
6. Irani AM, Butrus SI, Tabbara KF, Schwartz LB. Human conjunctival mast cells: distribution of MCT and MCTC in vernal conjunctivitis and giant papillary conjunctivitis. J Allergy Clin Immunol 1990; 86:34-40.
7. Woodward DF, Hawley SB, Williams LS, et al. Studies on the ocular pharmacology of prostaglandin D2. Invest Ophthalmol Vis Sci 1990; 31:138-146.
8. Leonardi A. Emerging drugs for ocular allergy. Expert Opin 2005; 10:505-519. Demonstrates immunopathogenesis as it is connected to different clinical profiles of allergy. A class review of existing treatments is covered. Introduces the role of pharmacoeconomics in allergy medicine development.
9. Abelson MB, Butrus SI, Weston JH, Rosner B. Tolerance and absence of rebound vasodilation after topical ocular decongestant usage. Ophthalmology 1984; 91:1364-1367.
10. Abelson MB, Welch DL. An evaluation of onset and duration of action of Patanol (opopatadine hydrochloride ophthalmic solution 0.1%) compared to Claritin (loratidine 10 mg) tablets in acute allergic conjunctivitis in the conjunctival allergen challenge model. Acta Ophthalmol Scand 2000; 78:60-63.
11. Grumetto L, Cennamo G, Del Prete A, et al. Pharmacokinetics of cetirizine in tear fluid after a single oral dose. Clin Pharmacokinet 2002; 41:525-531.
12. Deschenes J, Discepola M, Abelson MB. Comparative evaluation of olopatadine ophthalmic solution (0.1%) using the provocative antigen challenge model. Acta Ophthalmol Scand 1999; 77:47-52.
13. Mcghee CNJ, Dean S, Danesh-Meyer H. Locally administered ocular corticosteroids: benefits and risks. Drug Safety 2002; 25:33-55.
14. Tabbara KF, Al-Kharashi SA. Efficacy of nedocromil 2% versus fluorometholone 0.1%: a randomized double-masked trial comparing the effect on severe vernal keratoconjunctivitis. Br J Ophthalmol 1999; 83:180-184.
15. Bielory L, Lien KW, Bigelsen S. Efficacy and tolerability of newer antihistamines in the treatment of allergic conjunctivitis. Drugs 2005; 65:215-228. Concentrated review exploring pharmacodynamics and pharmacokinetics of newer antihistamines. Contains a comparison of the potency of available agents in terms of binding affinities or dissociation constants. Clinical trials on efficacy are also discussed. Contrasts dosage and half-life of various medications. Undesirable adverse effects covered.
16. Ciprandi G, Buscaglia S, Pesce GP, et al. Protective effect of loratadine on specific conjunctival provocation test. Int Arch Allergy Appl Immunol 1991; 96:344-347.
17. Simons FE, Prenner BM, Finn A Jr. Efficacy and safety of desloratadine in the treatment of perennial allergic rhinitis: Desloratadine Study Group. J Allergy Clin Immunol 2003; 111:617-622.
18. Ciprandi G, Buscaglia S, Pesce G, et al. Cetirizine reduces inflammatory cell recruitment and ICAM-1 (or CD54) expression on conjunctival epithelium in both early- and late-phase reactions after allergen-specific challenge. J Allergy Clin Immunol 1995; 95:612-621.
19. Ciprandi G, Tosca MA, Cosentino C, et al. Effects of fexofenadine and other antihistamines on components of the allergic response: adhesion molecules. J Allergy Clin Immunol 2003; 112 (4 Suppl):S78-S82.
20. Pipkorn U, Bende M, Hedner J, et al. A double-blind evaluation of topical levocabastine, a new specific H1 antagonist in patients with allergic conjunctivitis. Allergy 1985; 40:491-496.
21. Ahluwalia P, Anderson DF, Wilson SJ, et al. Nedocromil sodium and levocabastine reduce the symptoms of conjunctival allergen challenge by different mechanisms. J Allergy Clin Immunol 2001; 108:449-454.
22. Yanni JM, Miller ST, Gamache DA, Spellman JM, et al. Comparative effects of topical ocular anti-allergy drugs on human conjunctival mast cells. Ann Allergy Asthma Immunol 1997; 79:541-545.
23. Calonge M, Montero JA, Herreras JM, et al. Efficacy of nedocromil sodium and cromolyn sodium in an experimental model of ocular allergy. Ann Allergy Asthma Immunol 1996; 77:124-130.
24. Leonardi A, Borghesan F, Avarello A, et al. Effect of lodoxamide and disodium cromoglycate on tear eosinohil cationic protein in vernal keratoconjunctivitis. Br J Ophthalmol 1997; 81:23-26.
25. Abelson MB, Berdy GJ, Mundorf T, Amdahl LD, et al., Pemirolast Study Group. Pemirolast potassium 0.1% ophthalmic solution is an effective treatment for allergic conjunctivitis: a pooled analysis of two prospective, randomized, double-masked, placebo-controlled, Phase III studies. J Ocul Pharmacol Ther 2002; 18:475-488.
26. Leonardi A, Abelson MB. Double-masked, randomized, placebo-controlled clinical study of the mast cell-stabilizing effects of treatment with olopatadine in the conjunctival allergen challenge model in humans. Clin Ther 2003; 25:2539-2552.
27. Cook EB, Stahl JL, Barney NP, et al. Olopatadine inhibits antiimmunoglobulin E-stimulated conjunctival mast cell upregulation of ICAM-1 expression on conjunctival epithelial cells. Ann Allergy Asthma Immunol 2001; 87:424-429.
28. Cook EB, Stahl JL, Barney NP, et al. Olopatadine inhibits TNFalpha release from human conjunctival mast cells. Ann Allergy Asthma Immunol 2000; 84:504-508.
29. Woerly G, Loiseau S, Loyens M, et al. Inhibitory effects of ketotifen on eotaxin-dependent activation of eosinophils: consequences for allergic eye diseases. Allergy 2003; 58:397-406.
30. Ciprandi G, Buscaglia S, Catrullo A, et al. Azelastine eye drops reduce and prevent allergic conjunctival reaction and exert antiallergic activity. Clin Exp Allergy 1997; 27:182-191.
31. Kempuraj D, Huang M, Kandere-Grzybowska K, et al. Azelastine inhibits secretion of IL-6, TNF-alpha and IL-8 as well as NF-kappaB activation and intracellular calcium ion levels in normal human mast cells. Int Arch Allergy Immunol 2003; 132:231-239.
32. Saito H, Yamamoto N, Tomita S, et al. Effect of emedastine difumarate on CC chemokine-elicited eosinophil migration. Int Arch Allergy Immunol 2001; 125 (Suppl. 1):22-28.
33. Kayasuga R, Yukio S, Watanabe T, Kamei C. Participation of chemical mediators other than histamine in nasal allergy signs: a study using mice lacking histamine H1 receptors. Eur J of Pharmacol 2002; 449:287-291.
34. Amon U, Gibbs BF, Buss G, Nitschke M. In vitro investigations with the histamine H1 receptor antagonist, epinastine (WAL 801 CL), on isolated human allergic effector cells. Inflamm Res 2000; 49:112-116.
35. Matsushita N, Aritake K, Takada A, Hizue M, et al. Pharmacological studies on the novel antiallergic drug HQL-79: II. Elucidation of mechanisms for antiallergic and antiasthmatic effects. Jpn J Pharmacol 1998; 78:11-22.
36. Kayasuga R, Iba Y, Hossen MA, Watanabe T, et al. The role of chemical mediators in eosinophil infiltration in allergic rhinitis in mice. Int Immunopharmacol 2003; 3:469-473.
37. Kamei C, Mio M, Kitazumi K, Tsujimoto S, et al. Antiallergic effect of epinastine (WAL 801 CL) on immediate hypersensitivity reactions: (II) Antagonistic effect of epinastine on chemical mediators, mainly antihistaminic and anti-PAF effects. Immunopharmacol and Immunotoxicol 1992; 14:207-218.
38. Abelson MB, Chambers WA, Smith LM. Conjunctival allergen challenge: A clinical approach to studying allergic conjunctivitis. Arch Ophthalmol 1990; 108:84-88.
39. D'Arienzo PA, Leonardi A, Bensch G. Randomized, double-masked, placebo-controlled comparison of the efficacy of emadastine difumarate 0.05% ophthalmic solution and ketofen fumarate 0.025% ophthalmic solution in the human conjunctival allergen challenge model. Clin Ther 2002; 24:409-416.
40. Greiner JV, Udell IJ. A comparison of the clinical efficacy of pheniramine maleate/naphazoline hydrochloride ophthalmic solution and olopatadine hydrochloride ophthalmic solution in the conjunctival allergen challenge model. Clin Ther 2005; 27:568-577. Clinical trial of combination antihistamine-vasoconstrictor versus dual-action antihistamine-mast cell stabilizer. Describes the standard model of conjunctival allergen challenge (CAC) and primary end point measure of efficacy, the Ocular Allergy Index (OAI).
41. Tuft L, Ettelsson KN, Gupta K, Krenger C. Eye tests with inhalant allergens. J Allergy 1959; 30:492-505.
42. Corren J, Rachelefsky G, Spector S, et al. Onset and duration of action of levocabastine nasal spray in atopic patients under nasal challenge conditions. J Allergy Clin Immunol 1999; 103:574-580.
43. Bonini Se, Bonini St, Berruto A, Tomasini M, et al. Conjunctival provocation test as a model for the study of allergy and inflammation in humans. Int Arch Allergy Appl Immunol 1989; 88:144-148.
44. Avunduk AM, Tekelioglu Y, Turk A, Akyol N. Comparison of the effects of ketotifen fumarate 0.025% and olopatadine HCl 0.1% ophthalmic solutions in seasonal allergic conjunctivitis: a 30-day, randomized, double-masked, artificial tear substitute-controlled trial. Clinical Therapeutics 2005; 27:1392-1402. Clinical trial demonstrating the combined use of subjective clinical outcome measures and objective cytologic biomarker outcome measures following antiallergy treatment.
45. Center for Disease Control (CDC). National Center for Chronic Disease Prevention and Health Promotion. Health Related Quality of Life: How does the CDC measure population health related quality of life? http://www.cdc.gov/hrqol/ methods.htm. [Accessed 6 June 2006]
46. Alexander M, Berger W, Buchholz P, Walt J, et al. The reliability, validity and preliminary responsiveness of the Eye Allergy Patient Impact Questionnaire (EAPIQ). Health Qual Life Outcomes 2005; 3:67. Psychometric evaluation of available ocular allergy quality of life measuring instruments. Study compares the newer EAPIQ with the other available eye-specific and nonspecific standardized instruments: Mini Rhinoconjunctivitis Quality of Life Questionnaire, Health Utilities Index and the Health Status Change Questionnaire-Short Form.
47. Juniper EF, Thompson AK, Ferrie PJ, Roberts JN. Development and validation of the mini Rhinoconjunctivitis Quality of Life Questionnaire. Clin Exp Allergy 2000; 30:132-140.
48. Schiffman RM, Christianson MD, Jacobsen G, Hirsch JD, et al. Reliability and validity of the Ocular Surface Disease Index. Arch Ophthalmol 2000; 118:615-621.
49. Richard C, Bibas P, Lablache-Combier M, Allaire C. Comparison of three antiallergic eyedrops in a specific conjunctival provocation test: mequitazine, levocabastine and dexamethasone [in French]. J Fr Ophthalmol 2005; 28:244-250. Randomized, double-masked intra-individual trial of two antihistamines versus one corticosteroid.
50. Abelson MB, Greiner JV. Comparative efficacy of olopatadine 0.1% ophthalmic solution versus levocabastine 0.05% ophthalmic suspension using the conjunctival allergen challenge model. Curr Med Res and Opin 2004; 20:1953-1958.
51. Netland PA, Leahy C, Krenzer KL. Emedastine ophthalmic solution 0.05% versus levocabastine ophthalmic suspension 0.05% in the treatment of allergic conjunctivitis using the conjunctival allergen challenge model. Am J Ophthalmol 2000; 130:717-723.
52. Abelson MB, Gomes PJ, Vogelson CT, Pasquine TA, et al. Clinical efficacy of olopatadine hydrochloride ophthalmic solution 0.2% compared with placebo in patients with allergic conjunctivitis or rhinoconjunctivitis: a randomized, double-masked environmental study. Clin Therapeutics 2004; 26:1237-1248.
53. Lanier BQ, Finegold I, D'Arienzo P, Granet D, et al. Clinical efficacy of olopatadine vs epinastine ophthalmic solution in the conjunctival allergen challenge model. Curr Med Res Opin 2004; 20:1227-1233.
54. Canonica GW, Ciprandi G, Petzold U, Kolb C, et al. Topical azelastine in perennial allergic conjunctivitis. Curr Med Res Opin 2003; 19:321-329.
55. Nazarov O, Petzold U, Haase H, Nguyen DT, et al. Azelastine eye drops in the treatment of perennial allergic conjunctivitis. Arzneimittelforschung 2003; 53:167-173 [ABSTRACT].
56. Song JS, Jung HR, Kim HM. Effects of topical tranilast on corneal haze after photorefractive keratectomy. J Cataract Refract Surg 2005; 31:1065-1073. An immunohistochemical analysis on immune mediators of inflammatory corneal haze following photorefractive keratectomy. Immune mediator TGF may also be involved in inflammatory cascade of allergic conjunctivitis making this a new treatment to consider.
57. Kosrirukvongs P, Luengchaichawange C. Topical cyclosporine 0.5 per cent and preservative-free ketorolac tromethamine 0.5 per cent in vernal keratoconjunctivitis. J Med Assoc Thai 2004; 87:190-197 [ABSTRACT].
58. Bielory L, Ghafoor S. Histamine receptors and the conjunctiva. Curr Opin Allergy Clin Immunol 2005; 5:437-440. A salient review of histamine, histamine receptors, second messengers and downstream mechanisms of phospholipase C-dependent inositol phoshate pathway as they relate to allergy in the conjunctiva. Provides evidence of the subsequent role of immunologic mediators such as eosinophils, neutrophils, cytokines such as IL-1, IL-3, IL-5 and IL-6 signaling cellular infiltration, generalized inflammation, edema, itching, redness and vascular permeability.